April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intraocular contents of the vascular endothelial growth factor as a marker of diabetic retinopathy progression.
Author Affiliations & Notes
  • Dmitry Lipatov
    ophthalmology, Reserch Endocrinology Center, Moscow, Russian Federation
  • Anatoliy Kuzmin
    ophthalmology, Reserch Endocrinology Center, Moscow, Russian Federation
  • Timofey Chistaykov
    ophthalmology, Reserch Endocrinology Center, Moscow, Russian Federation
  • Yulia Bautina
    ophthalmology, Reserch Endocrinology Center, Moscow, Russian Federation
  • Marina Shestakova
    ophthalmology, Reserch Endocrinology Center, Moscow, Russian Federation
  • Footnotes
    Commercial Relationships Dmitry Lipatov, None; Anatoliy Kuzmin, None; Timofey Chistaykov, None; Yulia Bautina, None; Marina Shestakova, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dmitry Lipatov, Anatoliy Kuzmin, Timofey Chistaykov, Yulia Bautina, Marina Shestakova, ; Intraocular contents of the vascular endothelial growth factor as a marker of diabetic retinopathy progression.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1947.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To estimate the influence of the intraocular value vascular endothelial growth factor (VEGF) to the diabetic retinopathy (DR) progression in patients with diabetes mellitus (DM) been operaed due to cataract, and to determine the power of the VEGF assessment in the anterior chamber of eye (AChE) as a diagnostic test of the proliferative DR.

Methods: 420 patients with DM type 1 and type 2 been operated due to cataract (facoemulsification) were included in the study. During surgical procedure the fluids of the AChE were obtained for VEGF value analysis (by technique ELISA). All patients were surveyed under supervision of the ophthalmologist and endocrinologist before operation. Duration of the follow-up period after operation was not less than 12 months.

Results: All patients before operation did not differ by corrected distance visual acuity (CDVA), however proliferative DR was correctly diagnosed only in 50 % of cases because of the lens opacity. The average VEGF-A level in fluid of AChE in patients with DM, but without DR sings was 22,75 pg/ml. More severe DR tended to occur in diabetic patients with higher VEGF levels in AChE. In patients with non-proliferative DR VEGF value was 52,5 pg/ml, with pre-proliferative DR - 75,84 pg/ml and in proliferative DR reached 336,6 pg/ml. The differences were statistically significant, p <0,0001. Patients with high intraocular contents of the VEGF (more, than 140 pg/ml) had the worse prognosis of the DR progression. They were treated by laser coagulation of the retina in 1,19 times than patients with VEGF value in the AChE below 140 pg/ml, and they developed anterior chamber neovascularion in 12,3 times often (p=0,0004) than otherss. Anterior chamber neovascularion led to neovascular glaucoma.

Conclusions: High contents of the VEGF in fluid of the AChE is the predicted factor of the DR progression. Level VEGF in the AChE more than 140 pg/ml can be an additional criterion for the deterioration of the proliferation process of the eye in patients with DM.

Keywords: 499 diabetic retinopathy • 543 growth factors/growth factor receptors • 498 diabetes  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×